ASTonix

Company Overview

Snapshot

Founded in June 2026, ASTonix operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technology.

Business overview

ASTonix is a Health Tech & Life Sciences company specializing in Medical Devices, specifically Diagnostics Devices. The company develops iPRISM, a rapid phenotypic antibiotic susceptibility testing (AST) platform designed for point-of-care diagnosis of urinary tract infections (UTIs). This system aims to provide lab-level susceptibility results during a single patient visit, facilitating evidence-based antibiotic selection and supporting antimicrobial stewardship. The technology utilizes a label-free optical method to monitor bacterial growth dynamics and applies AI classification to generate susceptibility readouts. ASTonix targets clinics, emergency care, hospitals, and high-volume laboratories, with plans to expand beyond UTIs to other infectious diseases like sepsis and fungal infections.

Company Intelligence Q&A

What is ASTonix's primary focus?

ASTonix is focused on developing iPRISM, a rapid point-of-care antibiotic susceptibility testing (AST) platform for urinary tract infections (UTIs).

When was ASTonix founded?

ASTonix was founded in June 2026.

What technology does ASTonix utilize in its platform?

ASTonix's iPRISM platform uses a label-free optical method to monitor bacterial growth dynamics and applies AI classification to output susceptibility readouts.

Which markets does ASTonix target?

ASTonix targets clinics, emergency care, hospitals, and high-volume laboratories with its diagnostic platform.

What is the current product stage of ASTonix's technology?

ASTonix's iPRISM platform is currently in the Research & Development (R&D) stage, focusing on developing its core technology for rapid antibiotic susceptibility testing.